Why ‘Big Pharma’ Will Never Make a Cheap Anti-Aging Drug

In this ZeroHedge article, staff writers explain why Big Pharma is structurally disincentivized from developing and marketing affordable anti-aging treatments despite scientific potential.

• Pharmaceutical companies prioritize high-margin, patent-protected drugs for chronic conditions over one-time or low-cost interventions that could cure or prevent disease.
• Anti-aging therapies threaten recurring revenue streams from treatments for age-related illnesses like cancer, heart disease, and neurodegeneration, which generate billions annually.
• Regulatory hurdles, including lengthy FDA approval processes and requirements for specific disease indications rather than general “aging,” make broad anti-aging drugs economically unviable.
• Existing business models favor expensive biologics and maintenance therapies; a cheap, effective anti-aging pill would cannibalize multiple profitable drug categories.
• Investment flows toward incremental symptom management rather than root-cause longevity solutions, as the latter risks disrupting entrenched profit centers.
• Potential breakthroughs in senolytics, NAD boosters, or rapamycin analogs face funding and commercialization barriers due to misalignment with Big Pharma’s patent-and-profit incentives.
• Patients and society bear the cost of delayed innovation, while the industry focuses on managing rather than eradicating aging-related decline.

Read the full story:
https://www.zerohedge.com/medical/why-big-pharma-will-never-make-cheap-anti-aging-drug